DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Tuesday morning. The brokerage issued a hold rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright upped their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Price Performance

DBVT opened at $0.76 on Tuesday. The stock’s 50 day moving average price is $0.76 and its 200 day moving average price is $0.93. The stock has a market cap of $72.92 million, a P/E ratio of -0.82 and a beta of 0.67. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.14.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. Equities analysts anticipate that DBV Technologies will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.